Anti-Netrin-1 Antibody Combination Therapy for Cancer Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using immune checkpoint inhibitors, such as anti-PD1 and anti-CTLA4 antibodies, have limited efficacy and unpredictability, with only a fraction of patients responding, and there is a need to enhance their effectiveness, especially in cancers with netrin-1 expression.
Innovation Solution
Combining an anti-netrin-1 antibody with immune checkpoint inhibitors, such as anti-CTLA4 or anti-PD1, to disrupt netrin-1/netrin-1 receptor interaction, thereby modulating the tumor immune infiltrate and enhancing the presence of killer lymphoid cells, thereby boosting the efficacy of immunotherapeutic treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors (anti-PD1 or anti-CTLA4) are used alone, then the treatment mechanism is simple, but the efficacy is limited and unpredictable with only a fraction of patients responding
Solution Approach 1:
The patent combines anti-netrin-1 antibodies with immune checkpoint inhibitors (anti-PD1 or anti-CTLA4) into a dual-therapy regimen. This merging of two different treatment mechanisms targets both the netrin-1-mediated immune suppression pathway and the checkpoint inhibitor pathway simultaneously, thereby improving overall treatment efficacy and response rates compared to monotherapy
2Reliability
If combination therapy with anti-netrin-1 antibody and immune checkpoint inhibitor is used, then the efficacy is enhanced, but the treatment complexity increases
Solution Approach 1:
The combination therapy regimen is designed to serve multiple functions simultaneously: the anti-netrin-1 antibody blocks netrin-1-mediated immune cell migration and suppression, while the immune checkpoint inhibitor blocks checkpoint-mediated T cell suppression. This multi-functional approach allows a single treatment protocol to address multiple immune evasion mechanisms used by tumors, thereby enhancing efficacy despite increased complexity
3Productivity
If anti-netrin-1 antibody is combined with immune checkpoint inhibitor, then the immune response is enhanced by shifting T cell balance, but the device complexity increases
Solution Approach 1:
The anti-netrin-1 antibody acts as an intermediary that specifically blocks the netrin-1 signaling pathway, which is a key mediator of immune cell migration and suppression in the tumor microenvironment. By interrupting this intermediate signaling pathway, the treatment enhances the effectiveness of immune checkpoint inhibitors without requiring complete redesign of the overall immunotherapy approach
Data Source
AI summary
The present disclosure is directed to the combination or combined use of (i) a compound able to disrupt or impede netrin-1/netrin-1 receptors interaction or netrin-1-mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.